HEALEY ALS Platform Trial Webinar: January 22, 2026 | Research Access

Why It Matters

The trial’s accelerated, shared‑placebo design could bring effective ALS treatments to market sooner, while its patient‑focused enhancements lower participation barriers for a disease with limited options.

Key Takeaways

• Platform trial accelerates ALS drug testing through shared placebo groups
• New regimen I (NUZ001) launches, targeting patients within 24 months
• Trial duration shortened to 9 months placebo phase, then active extension
• Remote visits and biomarker refinements improve patient‑centric experience
• Over 70 sites listed; enrollment status updated on interactive website

Summary

The webinar hosted by the Healey Center at Mass General introduced the ongoing ALS platform trial, highlighted patient‑navigation resources, and announced the upcoming launch of a new drug regimen (NUZ001) in 2026.

Organizers explained how the platform trial uses a shared placebo arm to evaluate multiple investigational drugs, shortening the time to topline results. Since its 2020 debut, three regimens have completed, and the new regimen will enroll participants within 24 months of weakness onset, with a 9‑month randomized phase followed by an open‑label extension. Remote visits, refined biomarker panels, and stricter inclusion criteria (vital capacity ≥50%, ability to swallow) aim to make the study more patient‑centric.

Nurse Judy Kerry walked attendees through searchable databases such as ClinicalTrials.gov, ALS TDI navigator, veteran‑specific portals, and a geospatial clinic locator, emphasizing that patients need not be treated at the enrolling center. The team also showcased an interactive site map showing over 70 consortium sites and real‑time enrollment status.

By streamlining operations and expanding trial capacity, the platform promises faster identification of effective ALS therapies while offering broader access for patients nationwide. Stakeholders should monitor the website for site activation updates and consider enrollment before sites reach capacity.

Original Description

Catherine Small, Patient Navigator for the HEALEY ALS Platform Trial, and Judi Carey, RN, Research Access Nurse at Mass General, shared information about how to stay connected to ALS research, where to find reliable educational resources, and how to explore opportunities for participation.

Visit the Mass General website to register for future Platform Trial webinars: https://www.massgeneral.org/neurology/als/research/platform-trial-news

Sign up for the ALS Link to stay up to date about news and research from the Sean M. Healey & AMG Center for ALS: https://lp.constantcontactpages.com/sl/wQfOqgA/ALSLink

Follow MGH Neurology on Facebook (https://www.facebook.com/MGHNeurology/) and X (https://x.com/MGHNeurology)